Explore how cutting-edge agents like alpelisib, capivasertib, MEK and ERK inhibitors, and JAK inhibitors are reshaping the treatment landscape across subtypes.

Efficacy was consistent regardless of background therapy. Patients taking nerandomilast, an oral phosphodiesterase 4B (PDE4B) inhibitor, also experienced numerically fewer acute exacerbations ...

Nerandomilast is a preferential inhibitor of phosphodiesterase 4B (PDE4B) with antifibrotic and immunomodulatory effects, a mechanism different than approved antifibrotic treatments pirfenidone ...

Panelists discuss how currently available ALK inhibitors compare in terms of efficacy, durability of response, and central nervous system (CNS) penetration for metastatic non–small cell lung ...